Raghavan Kadalraja, Dedeepiya Vidyasagar Devaprasad, Ikewaki Nobunao, Sonoda Tohru, Iwasaki Masaru, Preethy Senthilkumar, Abraham Samuel Jk
Department of Paediatric Neurology, Kenmax Medical Services Pvt. Ltd, Madurai, India.
Department of Paediatric Neurology, Jesuit Antonyraj memorial Inter-disciplinary Centre for Advanced Rehabilitation and Education (JAICARE), Madurai, India.
BMJ Neurol Open. 2022 Jan 18;4(1):e000203. doi: 10.1136/bmjno-2021-000203. eCollection 2022.
Autism spectrum disorders (ASDs) are a wide range of behavioural disabilities for which there are no definite interventional modalities available. Remedial therapies remain the only option but with varying outcomes. We have evaluated the Childhood Autism Rating Scale (CARS) and alpha-synuclein levels in this parallel-group, multiple-arm pilot clinical study after supplementation with a biological response modifier beta-glucan food supplement (Nichi Glucan).
Six subjects with ASD (n=6) Gr. 1 underwent conventional treatment comprising remedial behavioural therapies and L-carnosine 500 mg per day, and 12 subjects (n=12) Gr. 2 underwent supplementation with the Nichi Glucan 0.5 g two times per day along with the conventional treatment.
There was a significant decrease in the CARS score in all of the children of the Nichi Glucan Gr.2 compared with the control (p=0.034517). Plasma levels of alpha-synuclein were significantly higher in Gr. 2 (Nichi Glucan) than in the control group Gr. 1 (p=0.091701).
Improvement of the behavioural pattern CARS score and a correlating alpha-synuclein level, followed by a safe beta-glucan food supplement, warrants further research on other parameters, such as gut-microbiota evaluation, and relevant neuronal biomarkers which is likely to cast light on novel solutions.
自闭症谱系障碍（ASD）是一系列行为障碍，目前尚无明确的干预方式。补救性治疗仍然是唯一的选择，但效果各异。在补充生物反应调节剂β-葡聚糖食品补充剂（Nichi Glucan）后，我们在这项平行组、多臂试点临床研究中评估了儿童自闭症评定量表（CARS）和α-突触核蛋白水平。
6名1级自闭症谱系障碍受试者（n = 6）接受包括补救性行为疗法和每日500毫克L-肌肽的常规治疗，12名2级受试者（n = 12）在接受常规治疗的同时，每天两次补充0.5克Nichi Glucan。
与对照组相比，Nichi Glucan 2级组所有儿童的CARS评分均显著降低（p = 0.034517）。2级组（Nichi Glucan）的血浆α-突触核蛋白水平显著高于对照组第1组（p = 0.091701）。
行为模式CARS评分的改善以及与之相关的α-突触核蛋白水平，继之以安全的β-葡聚糖食品补充剂，有必要对其他参数进行进一步研究，如肠道微生物群评估和相关的神经元生物标志物，这可能会为新的解决方案提供线索。
